Day 3 of the 2019 annual meeting of the American Academy of Ophthalmology features Fernando Arevalo, MD, FACS, as he shares findings from his presentation on using brolucizumab to treat neovascular age-related macular degeneration (AMD),
Judy E. Kim, MD; David M. Brown, MD; and Charles C.
According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.
Allen C. Ho, MD, discusses precision subretinal delivery for gene and cell therapy along with Ben Ko, engineering manager, Kaleidoscope Innovation, at the 2019 meeting of the American Academy of Ophthalmology in San Francisco, CA.
Nieraj Jain, MD, describes the investigations that led to the recent identification of this drug-related retinal toxicity and described the clinical features that support its diagnosis.
John T. Thompson, MD, discusses retinal relativity and reimbursement roulette during Day 2 of the 2019 American Academy of Ophthalmology's annual meeting.
Jennifer K. Sun, MD, discusses the treatment of centrally involved diabetic macular edema with better vision: Protocol V, at the 2019 American Academy of Ophthalmology's annual meeting in San Francisco, CA.
Tarek S. Hassan, MD, shares his findings on the predictors of post injection endophthalmitis: a multivariable analysis based on injection protocol and povidone iodine strength, at the 2019 American Academy of Ophthalmology.
Speakers at AAO 2019 event describe journey leading to approval of the first gene therapy for a genetic disease.
San Francisco is the city of new beginnings and a leader in education and culture-changing movements that ultimately affect the country and the world.